Stocks to Watch: JOE, BAH, TEA & More

Take a look at some of Wednesday's midday movers:


Forest Labs is holding its own on a down market day. Billionaire investor Carl Icahn plans to nominate another slate of directors to company's board. Icahn holds a 9.92 percent stake in the drugmaker.

St Joe fell after Greenlight Capital’s David Einhorn criticized the Florida developer again, saying the business model is flawed and the company still needs to take further write-downs on its unsold beachfront real estate.

Booz Allen Hamilton rose after the consulting firm reported a stronger-than-expected quarterly profit on growth at its defense, civil and intelligence businesses.

Steel stocks, including AK Steel ,U.S. Steel ,Nucor , and SteelDynamics fell as the euro continued to weaken.

Oil and oil services stocks slid as oil fell below the $90 a barrel. Exxon Mobil ,Chevron ,BP ,Halliburton , and Schlumberger were all lower.

Darden Restaurants skidded after BofA Merrill removed the restaurant company from its US 1 list.

Specialty tea retailer Teavana Holdings plunged after the company reported lower-than-expected quarterly revenue on tepid sales at its stores open at least a year.

Monsanto moved higher after the global agricultural company raised its fiscal guidance for 2012, and said strong growth would continue in 2013.

Macy’s lower despite reporting better than expected May same store sales, helped by its growing e-commerce business. Other department stores, including Sears ,Kohl’s , and JC Penney also weakened.

Homebuilders moved lower after a report showed pending home prices unexpectedly fell 5.5 percentin April to a four month low. Lennar ,DRHorton ,KB Homes , and Pulte all to the downside.

Coal stocks among the commodities that fell. Peabody Energy ,Walter Energy ,Consol Energy , Alpha Natural , and Arch Coal all lower.

Human Genome Sciences lower on a Reuters report that GlaxoSmithKline will likely begin a campaign to replace the entire Human Genome board. This as its steps up its $2.6 billion hostile bid for the biotech company.

Questions? Comments? Email us at